Fosmanogepix(APX001)是一种口服广谱抗真菌(antifungal)药物，靶向高度保守的Gwt1真菌酶。Fosmanogepix(APX001)是一种N-磷酸氧基甲基前药，由全身碱性磷酸酶快速完全代谢为活性部分APX001A，可用于研究侵袭性真菌感染的开发。
Fosmanogepix (APX001) is a first-in-class and orally available broad-spectrum antifungal agent, which targets the highly conserved Gwt1 fungal enzyme. Fosmanogepix (APX001) is an N-phosphonooxymethyl prodrug which is rapidly and completely metabolized by systemic alkaline phosphatases to the active moiety, APX001A. Fosmanogepix (APX001) can be used in development for the treatment of invasive fungal infections[1][2].
[1]. Shaw KJ, et al. In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00523-18. [2]. Gebremariam T, et al. APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01713-18.
动态评分
0.0